Search Results - "Falcoz, C"

Refine Results
  1. 1

    Experimental investigations on showerhead cooling on a blunt body by Falcoz, C., Weigand, B., Ott, P.

    “…In modern gas turbines, the turbine airfoil leading edge is currently protected from the hot gases by specific film cooling schemes, so-called showerhead…”
    Get full text
    Journal Article
  2. 2

    A comparative study on showerhead cooling performance by Falcoz, C., Weigand, B., Ott, P.

    “…In modern gas turbines, the turbine airfoil leading edge is currently protected from the hot gas by specific film cooling schemes, so called showerhead…”
    Get full text
    Journal Article
  3. 3

    Pharmacokinetics-Pharmacodynamics of a Sordarin Derivative (GM 237354) in a Murine Model of Lethal Candidiasis by Aviles, P, Falcoz, C, San Roman, R, Gargallo-Viola, D

    Published in Antimicrobial Agents and Chemotherapy (01-09-2000)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  4. 4

    Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration by MÖLLMANN, H, WAGNER, M, MEIBOHM, B, HOCHHAUS, G, BARTH, J, STÖCKMANN, R, KRIEG, M, WEISSER, H, FALCOZ, C, DERENDORF, H

    Published in European journal of clinical pharmacology (01-02-1998)
    “…To evaluate the pharmacokinetic and systemic pharmacodynamic properties of inhaled fluticasone propionate (FP). Single doses of 0.25, 0.5, 1.0 and 3.0 mg FP…”
    Get full text
    Journal Article
  5. 5

    Salmeterol and fluticasone propionate given as a combination : Lack of systemic pharmacodynamic and pharmacokinetic interactions by KIRBY, S, FALCOZ, C, DANIEL, M. J, MILLERI, S, SQUASSANTE, L, ZIVIANI, L, VENTRESCA, G. P

    “…To investigate the potential for systemic pharmacodynamic and pharmacokinetic interactions between inhaled salmeterol and fluticasone propionate when repeat…”
    Get full text
    Journal Article
  6. 6

    Correlation between In Vitro and In Vivo Activities of GM 237354, a New Sordarin Derivative, against Candida albicans in an In Vitro Pharmacokinetic-Pharmacodynamic Model and Influence of Protein Binding by AVILES, P, FALCOZ, C, GUILLEN, M. J, ROMAN, R. San, GOMEZ DE LAS HERAS, F, GARGALLO-VIOLA, D

    Published in Antimicrobial Agents and Chemotherapy (01-10-2001)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  7. 7

    The Bayesian analysis of a pivotal pharmacokinetic study by Rahman, N., Wakefield, J., Stephens, D., Falcoz, C.

    Published in Statistical methods in medical research (01-09-1999)
    “…The aim of this paper is to carry out a detailed Bayesian population pharmacokinetic analysis of a three-period cross-over study of the drug fluticasone…”
    Get full text
    Journal Article
  8. 8

    The Bayesian analysis of a pivotal pharmacokinetic study by Rahman, N J, Wakefield, J C, Stephens, D A, Falcoz, C

    Published in Statistical methods in medical research (01-09-1999)
    “…The aim of this paper is to carry out a detailed Bayesian population pharmacokinetic analysis of a three-period cross-over study of the drug fluticasone…”
    Get full text
    Journal Article
  9. 9

    Pharmacokinetics of teicoplanin in renal failure by FALCOZ, C, FERRY, N, POZET, N, CUISINAUD, G, ZECH, P. Y, SASSARD, J

    Published in Antimicrobial Agents and Chemotherapy (01-08-1987)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  10. 10

    Evaluation of pemetrexed (PEM) dosing paradigms using exposure-response relationships (ERRs) by Latz, J., Claret, L., Symanowski, J., Falcoz, C., Bruno, R., Smith, I., Calvert, H.

    Published in Journal of clinical oncology (20-06-2007)
    “…Abstract only 2530 Background: PEM is primarily renally eliminated and dosed based on body surface area (BSA). A direct relationship exists between creatinine…”
    Get full text
    Journal Article
  11. 11

    The relationship between pemetrexed exposure (AUC) and clinical outcome in Japanese NSCLC patients by Adachi, S., Tamura, T., Nakagawa, K., Falcoz, C., Musib, L., Calvert, H.

    Published in Journal of clinical oncology (20-06-2007)
    “…Abstract only 18041 Background: The efficacy of pemetrexed (PEM) 500 mg/m 2 administered with vitamin B 12 and folic acid (FS) has been established in…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers by Falcoz, Christine, Jenkins, Julian M., Bye, Carole, Hardman, Timothy C., Kenney, Kathy B., Studenberg, Scott, Fuder, H., Prince, William T.

    Published in Journal of clinical pharmacology (01-08-2002)
    “…These two Phase I, open‐label, single‐dose, randomized, crossover studies in 40 healthy male subjects investigated the pharmacokinetic and safety profiles of…”
    Get full text
    Journal Article
  14. 14

    Disposition of 1,2,3-trichloropropane in the Fischer 344 rat: conventional and physiological pharmacokinetics by Volp, R F, Sipes, I G, Falcoz, C, Carter, D E, Gross, J F

    Published in Toxicology and applied pharmacology (01-08-1984)
    “…To investigate the disposition of 1,2,3-trichloropropane (TCP), [14C]-TCP was administered iv to male Fischer 344 rats. Unchanged TCP and total radiolabel were…”
    Get more information
    Journal Article
  15. 15

    Distribution, metabolism, and elimination of phenobarbital in rats: physiologically based pharmacokinetic model by Engasser, J M, Sarhan, F, Falcoz, C, Minier, M, Letourneur, P, Siest, G

    Published in Journal of pharmaceutical sciences (01-11-1981)
    “…The distribution, metabolism, and elimination kinetics at two different doses of phenobarbital were examined in rats. After intravenous injection,…”
    Get more information
    Journal Article
  16. 16

    Bioavailability of orally administered micronised fluticasone propionate by Falcoz, C, Oliver, R, McDowall, J E, Ventresca, P, Bye, A, Daley-Yates, P T

    Published in Clinical pharmacokinetics (2000)
    “…The aim of this study was to determine the absolute oral bioavailability of fluticasone propionate (FP) in healthy volunteers. A 3-period incomplete block…”
    Get full text
    Journal Article
  17. 17

    Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers by Brindley, C, Falcoz, C, Mackie, A E, Bye, A

    Published in Clinical pharmacokinetics (2000)
    “…The aim of this analysis was to assess the rate and extent of systemic availability of inhaled fluticasone propionate (FP) from 2 dry powder systems (Diskhaler…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers by Mackie, A E, McDowall, J E, Falcoz, C, Ventresca, P, Bye, A, Daley-Yates, P T

    Published in Clinical pharmacokinetics (2000)
    “…The aim of these studies was to determine the absolute bioavailability in healthy volunteers of inhaled fluticasone propionate (FP) administered as a single…”
    Get full text
    Journal Article
  20. 20

    Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate by Rohatagi, S, Bye, A, Falcoz, C, Mackie, A E, Meibohm, B, Möllmann, H, Derendorf, H

    Published in Journal of clinical pharmacology (01-10-1996)
    “…Fluticasone propionate (FP) is a new corticosteroid that has been developed for the treatment of asthma. The compound has a very high receptor affinity, 18…”
    Get more information
    Journal Article